Case Reports

A novel treatment approach prolonging survival in an uncommon metastatic primary bladder adenocarcinoma


 

Primary bladder adenocarcinoma is an epithelial malignancy with pure glandular differentiation, without evidence of typical urothelial (transitional cell) carcinoma. PBA is rare, accounting for 0.5%-2% of all malignant bladder neoplasms, and it is seen more frequently in men than in women and is commonly diagnosed in the sixth decade of life.1-3 Clinical presentation includes hematuria and symptoms of bladder irritation.2

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Combination of celecoxib, zoledronic acid benefits some with hormone-sensitive prostate cancer
MDedge Hematology and Oncology
Poorer survival of African Americans with kidney cancer may be due to genomic differences
MDedge Hematology and Oncology
Adjuvant chemotherapy boosts survival for patients with locally advanced bladder cancer
MDedge Hematology and Oncology
Testicular cancer patients who fare well early on have smooth sailing thereafter
MDedge Hematology and Oncology
Hypofractionated radiation emerges as new standard of care for prostate cancer
MDedge Hematology and Oncology
Enzalutamide cuts disease progression, death in CRPC
MDedge Hematology and Oncology
ADT resistance signature predicts failure of hormone therapy for prostate cancer
MDedge Hematology and Oncology
Statins don’t appear to compromise effectiveness of abiraterone
MDedge Hematology and Oncology
Bipolar androgen therapy may be new option for hormone-sensitive prostate cancer
MDedge Hematology and Oncology
Diet, lifestyle factors add up in reducing risk of prostate cancer death
MDedge Hematology and Oncology